New Cell Therapy Reduces Mortality for COVID-19-related ARDS
An initial trial suggests invariant natural killer cell therapy improves survival.
An initial trial suggests invariant natural killer cell therapy improves survival.
The FDA is providing information on oxygenator devices used in extracorporeal circulation following a recall notice by Getinge/Maquet.
For critically ill COVID-19 patients treated with ECMO, the risk of death remains high - but is much lower than what was suggested by initial studies, a new report suggests.
The systems support influenza patients in recovery from severe respiratory problems.
Read MoreECMO may be considered a bridge to interventional catheterization, given a rapidly deteriorating patient, a high-risk intervention, and a reasonable expectation of recovery of cardiac function following intervention.
Read More